Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo

NCT00194714 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00194714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00194714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2016
Completion date
May 22, 2023
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2/neu positive, hla-a2 positive cells present, stage iv breast cancer, stage iv ovarian cancer